“Medtronic has exercised its rights to terminate its agreement to acquire EOFlow as a result of multiple breaches on their part,” the company said in the filing. The devicemaker did not share details on the alleged breaches.
Medtronic entered into a definitive agreement to acquire the South Korea-based company in May and, at the time, expected the deal to close by the end of the year. EOFlow makes a fully disposable insulin delivery-device that is worn as a patch on the skin, which Medtronic was planning to incorporate into its global diabetes business, according to the Star Tribune.
“We remain steadfast in our commitment to bringing a differentiated patch pump to market that integrates our most advanced [continuous glucose monitor] platform and clinically proven meal detection technology algorithm,” Medtronic said in a statement to the publication.
The scrapped deal comes as EOFlow faces several legal issues, including a lawsuit filed by the Massachusetts-based device company Insulet Corp., accusing the company of stealing trade secrets.
Editor’s note: Becker’s has reached out to EOFlow for comment and will update the article if more information becomes available.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
